Special channel feed – Endpoints News

SIGN UP

Special channel feed

The Endpoints 100 survey: CEOs changed the way biotechs operate during the pandemic. Things will never be the same again

3 years ago

The 20(+1) under 40: Inside the next generation of biotech leaders

3 years ago

The 2021 top 100 biopharma investors: As the pandemic hit and IPOs boomed, VCs swung into action like never before

3 years ago

2020’s NDA list is packed with commercial firsts — from historic to haphazard. Have we reached a tipping point?

3 years ago

Special report: Twenty extraordinary women blazing trails in biopharma R&D — Covid-19 and beyond

3 years ago

The Endpoints 11: Here are some of the most promising startups in biotech. And Covid-19 isn't going to stop them

3 years ago

The 20 under 40: Inside the next generation of biopharma leaders

4 years ago

The E100 biotech survey: Execs are hunkering down for the pandemic, worried about longterm fallout — but eager to see biopharma make a difference

4 years ago

The top 10 biopharma pipeline blowups, setbacks and snafus for H2 2019

4 years ago

Here are the 52 new drugs approved by the FDA in 2019. Who won? Who lost? And who just survived to 2020?

4 years ago

Special report: Twenty extraordinary women in biopharma R&D who worked their way to the top

4 years ago

The $102B club: The top 15 R&D spenders in the global biopharma business — 2019 edition

4 years ago

The top 10 pipeline blowups, setbacks and snafus for H1 2019

4 years ago

Biotech execs predict big M&A deals ahead as mood shifts in wake of a 2018 hangover — Endpoints 100

5 years ago

The top 10 pipeline blowups, setbacks and snafus for H2 2018

5 years ago

The 2018 breakdown on a chart-topping set of new drug approvals — and the 5 big things we learned from it

5 years ago

The top 10 stories from Endpoints News in 2018

5 years ago

What do Martin Shkreli, Gilead and Takeda have in common? They all figure prominently in the new top-20 list of the world’s most expensive drugs

5 years ago

A go-go FDA is poised to break the all-time record on new drug approvals. Is this the new standard for biopharma success?

5 years ago

Global reach: The top 25 biopharma companies in the world

5 years ago

The biotech mood at the halfway mark of 2018? Boisterous, focusing more attention on China and looking for accelerated progress

5 years ago

Who are the most productive drug developers in biopharma? Our top-20 list has lots of surprises

5 years ago

Top 10 pipeline blowups, setbacks and snafus in H1 2018

5 years ago

12 top China VCs you need to know who are making a transpacific splash (Part 2)

5 years ago

First page Previous page 123 Next page Last page